Hirotaka Kashiwagi

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hirotaka Kashiwagi. Retrieved from https://idiyas.com/inventor/hirotaka-kashiwagi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 78.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 8.4

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Gotenba, JP (2015)
Shizuoka, JP (2006 - 2023)

Company Filing History:

14 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

Years Active: 2006-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410168 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2025-09-09),

2. 12331050 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2025-06-17),

3. 12331049 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2025-06-17),

4. RE50455 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2025-06-10),

5. 12187724 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2025-01-07),

6. 11814381 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2023-11-14),

7. 10858356 - Pyrazolopyridine derivative having GLP-1 receptor agonist effect (2020-12-08),

8. 9499553 - Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same (2016-11-22),

9. 9221753 - Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds (2015-12-29),

10. 7994318 - Coumarin derivatives useful as TNFα inhibitors (2011-08-09),

11. 7935688 - Vitamin D-like compound (2011-05-03),

12. 7872142 - Coumarin derivatives useful as TNFα inhibitors (2011-01-18),

13. 7709664 - Coumarin derivatives useful as TNFα inhibitors (2010-05-04),

14. 7026491 - Coumarin derivatives useful as TNFα inhibitors (2006-04-11),

Title: Hirotaka Kashiwagi: Innovator in Diabetes Treatment

Introduction

Hirotaka Kashiwagi is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for diabetes and obesity. With a total of 14 patents to his name, Kashiwagi's work is recognized for its innovative approach to addressing critical health issues.

Latest Patents

One of his latest patents includes a pyrazolopyridine derivative that exhibits GLP-1 receptor agonist effects. This invention provides a compound characterized by a specific structural formula, where the indole ring and the pyrazolopyridine structure are interconnected through a substituent. The compound, along with its salts or solvates, serves as a preventative or therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) and obesity. This groundbreaking work highlights his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Kashiwagi is currently employed at Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His role at the company allows him to leverage his expertise in drug development and innovation. Throughout his career, he has focused on creating effective treatments that can significantly enhance the quality of life for individuals suffering from chronic conditions.

Collaborations

Kashiwagi has collaborated with notable colleagues, including Nobuyuki Hori and Satoshi Tsuchiya. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation in their field.

Conclusion

Hirotaka Kashiwagi stands out as a key figure in the pharmaceutical industry, with a strong focus on developing innovative solutions for diabetes and obesity. His contributions through patents and collaborations reflect his dedication to improving healthcare and advancing medical research.

Profile summary based on public USPTO records.